Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Adamis Pharma (ADMP – Research Report), G1 Therapeutics Inc (GTHX – Research Report) and Eyenovia Inc (EYEN – Research Report).
Adamis Pharma (ADMP)
B.Riley FBR analyst Andrew D’silva reiterated a Hold rating on Adamis Pharma today and set a price target of $1.10. The company’s shares closed last Monday at $1.11, close to its 52-week low of $0.93.
“Adamis (ADMP) reported 2Q19 results Thursday, 8/8, and reported a top-line/EPS came in at $5.8M/$(0.16), versus our/consensus estimates of $6.0M/$(0.15) and $6.1M/$(0.12), respectively. ADMP’s top-line was impacted by lower Symjepi sales, as only $1.1M was recognized from the offering vs. our $1.3M projection. Meanwhile, ADMP exited the quarter with $4.1M in cash, $2.3M in debt (all current liabilities), and a current ratio of 1.0:1.0. Subsequent to 2Q19’s end, ADMP raised $13.8M in gross proceeds through the issuance of 13.8M shares of common stock at $1 per share. The transaction included 1:1 warrant coverage (strike price of $1.15). The deal was not a surprise as we were modeling the company accessing the capital markets during 3Q19, but were modeling ADMP raising $19M at $1 per share.”
According to TipRanks.com, D’silva is a 3-star analyst with an average return of 2.7% and a 38.5% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals Inc, Anixa Biosciences Inc, and Sensus Healthcare Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adamis Pharma with a $3.55 average price target.
G1 Therapeutics Inc (GTHX)
In a report released today, Harshita Polishetty from B.Riley FBR reiterated a Buy rating on G1 Therapeutics Inc, with a price target of $55. The company’s shares closed last Monday at $31.45.
“Last week (08/07), G1 Therapeutics announced 2Q19 results and provided a corporate update on its pipeline. The most notable event the company reported was trilaciclib’s breakthrough therapy designation (BTD) in myelopreservation, which was awarded by the FDA based on data from three small-cell lung cancer (SCLC) Phase II trials. With regard to trilaciclib on the survival front, G1 provided an update in June, which indicated that patients receiving trilaciclib and chemotherapy (gemcitabine/carboplatin) had a statistically significant improvement in overall survival (OS) compared to those receiving chemotherapy alone.”
According to TipRanks.com, Polishetty is a 4-star analyst with an average return of 27.5% and a 61.9% success rate. Polishetty covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Karyopharm Therapeutics, and Mirati Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for G1 Therapeutics Inc with a $58.50 average price target, a 97.3% upside from current levels. In a report issued on August 8, Cowen & Co. also maintained a Buy rating on the stock.
Eyenovia Inc (EYEN)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Eyenovia Inc today and set a price target of $12. The company’s shares closed last Monday at $3.31.
“Our price target is derived from a market value of the firm at $250M, which includes a discounted cash flow-based asset value for all four micro-dosing products, with a 15% discount rate and 1% terminal growth rate, and assuming 20.7M shares outstanding at the end of 2Q20. Probabilities of success assigned are 80%, 80%, 55% and 45% for MicroPine, respectively.”
According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -18.9% and a 31.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Stealth Biotherapeutics Corp, and Aerpio Pharmaceuticals Inc.
Eyenovia Inc has an analyst consensus of Moderate Buy, with a price target consensus of $12.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.